Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bone Biologics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bone Biologics's regulatory disclosures and financial reporting.
Bone Biologics Corp reported an insider equity award for its Chief Executive Officer, Jeff Frelick. On January 8, 2026, he received an employee stock option grant covering 16,668 shares of common stock with an exercise price of $1.55 per share. The filing states that this option was granted under the company’s 2015 Equity Incentive Plan, is exempt under Rule 16b-3, and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
After this grant, Frelick directly holds 16,668 of these new options, along with previously held, fully vested options on 9,019 shares at an exercise price of $5.82 and options on 8 shares at an exercise price of $73,800. He also directly owns 360 shares of Bone Biologics common stock.
Bone Biologics Corporation filed a current report to share that its Chief Executive Officer issued a letter to stockholders. On September 4, 2025, the company released a press release discussing this CEO letter, and that press release is attached as Exhibit 99.1 to the report and incorporated by reference. The company’s common stock and related warrants trade on the Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.
Bone Biologics Corporation is updating its shelf registration statement on Form S-3 to carry forward $17,592,964 of previously registered but unsold securities under Rule 415(a)(6). The company states that, upon effectiveness of this new registration, the offering of these unsold securities under its prior registration statement (File No. 333-265872) will be deemed terminated and the previously paid $1,630.87 filing fee will be applied to this filing. This Amendment No. 1 is being filed solely to add the consent of its independent registered public accounting firm as Exhibit 23.1, with all other parts of the registration statement unchanged.
Bone Biologics (Nasdaq: BBLG / BBLGW) filed an 8-K (Item 8.01) reporting that Nasdaq’s Listing Qualifications Department confirmed on June 25 2025 the company has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share. The confirmation removes the prior deficiency notice and the immediate risk of delisting from the Nasdaq Capital Market.
The disclosure, delivered via a press release furnished as Exhibit 99.1, contains no additional financial data, share issuances, or operational updates. By maintaining its listing, the company preserves liquidity, institutional access, and market visibility—factors critical to future capital-raising efforts.